Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia

• Status: Completed
• Trial end date: 2007-08-01

Summary

This study is to understand how the inhaled form of amikacin is spread throughout the human body and how it is eliminated from the body and to make sure that giving an inhaled form of Amikacin to patients is safe and well tolerated

• Phase: Phase 2

Details

• Lead Sponsor: Bayer
• Collaborator: Nektar Therapeutics
• Treatments: Amikacin